777859-74-2

Usage

Uses

Used in Pharmaceutical Industry:
Benzoic acid, 2-bromo-6-(bromomethyl)-, methyl ester serves as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Benzoic acid, 2-broMo-6-(broMoMethyl)-, Methyl ester is also utilized as an intermediate in the production of agrochemicals, contributing to the creation of pesticides and other agricultural products that enhance crop protection and yield.
Used in Chemical Industry:
Benzoic acid, 2-bromo-6-(bromomethyl)-, methyl ester acts as a building block for the synthesis of a wide range of organic compounds. Its versatility in chemical reactions makes it valuable for developing new materials and advancing chemical research.

Upstream product

• 99548-56-8 methyl 2-bromo-6-methyl-benzoate 
• 4389-50-8 2-amino-6-methylbenzoic acid 
• 535961-79-6 2-bromo-6-methylbenzoyl chloride 
• 90259-31-7 2-bromo-6-methylbenzoic acid 

Downstream Products

• 1417188-96-5 7-(4-Fluorophenyl)-2-(2-thieno[3,2-b]pyridin-5-ylethyl)isoindolin-1-one 
• 200049-46-3 7-bromo-2,3-dihydro-1H-isoindol-1-one 
• 1261277-83-1 7-bromo-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)isoindolin-1-one 
• 1261277-01-3 C₂₅H₂₀ClN₃O₂ 
• 1056950-89-0 2-bromo-6-formyl-benzoic acid methyl ester 
• 1021439-93-9 7-bromo-2-(4-t-butyl-phenyl)-2,3-dihydro-isoindol-1-one 

Relevant academic research and scientific papers

ISOINDOLINES AS HDAC INHIBITORS

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs), having the formula: (I) wherein Z, X1, X2, Y1, Y2, Y3, L, Z, and R are described herein.

Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11

N-Hydroxy-2-arylisoindoline-4-carboxamides are potent and selective inhibitors of HDAC11. The discovery, synthesis, and structure activity relationships of this novel series of inhibitors are reported. An advanced analog (FT895) displays promising cellular activity and pharmacokinetic properties that make it a useful tool to study the biology of HDAC11 and its potential use as a therapeutic target for oncology and inflammation indications.

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

The present invention relates to novel carboxamide compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating or controlling medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders

PHARMACEUTICAL PRODUCT CONTAINING LACTAM OR BENZENE SULFONAMIDE COMPOUND

The present invention provides, for example, the following compounds as a pharmaceutical composition for treating diseases induced by production, secretion or deposition of amyloid β proteins. The present invention provides a pharmaceutical composition for suppressing amyloid β production comprising a compound of the formula: wherein A is a benzene ring, a pyridine ring or a pyrimidine ring, X is sultam, lactam, sulfonamide or the like, C is substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl or the like, R2, R3 and R4 are each independently hydrogen, halogen, hydroxy, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy or the like, its pharmaceutically acceptable salt or a solvate thereof.

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, 0 and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use

Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF

Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1 6alkylthio, hydroxy, amino, mono or di C1 6alkylamino, an N-linked 4 to 7 memb

Suzuki couplings with phthalimidines - An efficient route to staurosporinone analogs

Staurosporinone analogs have been prepared by an efficient process. The key step is a palladium mediated Suzuki coupling between a bromophthalimidine and an aromatic boronic acid.